Further investigation identified a drug-responsive gene, PELI2, which may confer PI sensitivity, and in vitro experiments and computational analysis further confirmed that PELI2 presents a predictive biomarker of the PI responsiveness in MM patients. The gene discussed is PELI2; the disease is Miyoshi myopathy.